MedsChat.com

The People's Medicine Community ®
Drug Index: 

Zavesca

Active Ingredient(s): Miglustat
FDA Approved: July 31, 2003
Pharm Company: ACTELION PHARMS
Category: Enzymes

Welcome to the Zavesca information hub. Scroll down to read supplemental details and discuss this drug.


Zavesca Overview

Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Actelion and is used primarily to treat Type I Gaucher disease (GD1). It is marketed under the trade name Zavesca. Miglustat is an imino sugar, a synthetic analogue of D-glucose[1] and a white to off-white crystalline solid that has a bitter taste. The primary pharmacological activity of miglustat is inhibition of the enzyme glucosylceramide synthase, catalyzing the first step in the biosynthesis of glycosphingolipids (GSL),...

Read more Zavesca Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: http://en.wikipedia.org/wiki/Miglustat

Recent Zavesca Forums: RSS Feed

zavesca
Treatment for Type 1 Gaucher ## Zavesca contains the active ingredient Miglustat. Common side effects may include: nausea, back pain, constipation and weight loss. You can read more here: Do you have any other questions?
Updated 4 years ago.
   1  Subscribe to thread 195345

Possible Dosages for this and Related Drugs:

Miglustat
  • Capsule: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Miglustat or a similar ingredient: (1 result)


Possibly related Zavesca Topics:

zavesca Treatment for Type 1 Gaucher ## Zavesca contains the active ingredient Miglustat. Common side effects may include: nause...  1